<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02139410</url>
  </required_header>
  <id_info>
    <org_study_id>IGF-001</org_study_id>
    <nct_id>NCT02139410</nct_id>
  </id_info>
  <brief_title>IGF-1, Sarcopenia and Mortality: a Cohort Study in Patient With Cognitive Impairment</brief_title>
  <acronym>ISAAC</acronym>
  <official_title>Insulin Like Growth Factor 1 and Risks of Sarcopenia and Mortality in Patients With Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin-like growth factor 1 (IGF)-1 is an important neuromyotrophic hormone. Disregulation
      of this hormone has been reported to influence the genesis of cognitive impairment and
      dementia in the elderly patients. We analyzed the possible link between IGF-1 and risk of
      Sarcopenia and Mortality in a cohort of elder patients with cognitive impairment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>IGF-1 reduction in patients with sarcopenia</measure>
    <time_frame>baseline, 24 months, 48 months</time_frame>
    <description>IGF-1 reduction could be linked to sarcopenia in patients with cognitive impairment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IGF-1 reduction and mortality in patients with cognitive impairment</measure>
    <time_frame>baseline, 24 months, 48 months</time_frame>
    <description>IGF-1 could be an independent risk factor for mortality in patients with cognitive impairment</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">589</enrollment>
  <condition>Cognitive Impairment</condition>
  <condition>Insulin-like Growth Factor 1</condition>
  <arm_group>
    <arm_group_label>IGF-1 1st and 2nd quartile</arm_group_label>
    <description>Reduction of IGF-1 serum value in a cohort of patients with cognitive impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IGF-1 3rd and 4rd quartile</arm_group_label>
    <description>Reduction of IGF-1 serum value in a cohort of patients with cognitive impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IGF-1 serum value</intervention_name>
    <description>Evaluation of IGF-1 serum value at baseline, 24 and 48 months</description>
    <arm_group_label>IGF-1 1st and 2nd quartile</arm_group_label>
    <arm_group_label>IGF-1 3rd and 4rd quartile</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients were enrolled from orthopedics clinic (IRCCS Galeazzi Milan) and
        geriatric day service (Sapienza University of Rome)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of cognitive impairment (MMSE &lt; 24)

          -  Age &gt; 65 ys

        Exclusion Criteria:

          -  Diagnosis of pancreatic disorders

          -  Diagnosis of acromegaly

          -  Diagnosis of GH-related disorders

          -  Recent bone fractures or immobility before the enrollment (3 months)

          -  Cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincenzo Gianturco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sapienza University of Rome</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS Galeazzi</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapienza University of Rome</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2014</study_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Vincenzo Gianturco</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>sarcopenia</keyword>
  <keyword>mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mecasermin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

